Hydromorphone - Daiichi Sankyo

Drug Profile

Hydromorphone - Daiichi Sankyo

Alternative Names: DS-7113; DS-7113b; Hydromorphone HCl - Daiichi Sankyo; Hydromorphone hydrochloride - Daiichi Sankyo; Narurapid Tablets; Narusus Tablets

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Cancer pain

Most Recent Events

  • 30 Mar 2017 Registered for Cancer pain in Japan (PO, Controlled release)
  • 30 Mar 2017 Registered for Cancer pain in Japan (PO, Immediate release)
  • 02 Feb 2017 Daiichi Sankyo announces intention to seek approval or launch hydromorphone IV and SC formulations in 2018 (Daiichi Sankyo pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top